Soft Robotic Implant Surface for Reducing Fibrotic Encapsulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Implantable medical devices face significant limitations due to fibrotic encapsulation, leading to device failure and increased morbidity, with existing strategies providing limited success in mitigating foreign body responses.

Innovation Solution

The implementation of soft robotic capsules on the device's surface, actuated to cause cyclical deflection of the soft tissue interfacing membrane, altering biomechanics and reducing fibrous capsule thickness by modulating strain, fluid flow, and cellular activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional implantable medical devices are implanted, then device functionality is achieved, but fibrotic encapsulation occurs leading to device failure

Engineering Contradiction:

Improvedevice functionalityVSAvoidfibrotic encapsulation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies dynamics by incorporating an actuatable capsule that can change its state from a deflated to an inflated configuration. This dynamic structure allows the device to actively modulate the biomechanics of the soft tissue interface, transforming a static foreign body into an interactive system that can reduce fibrotic encapsulation through cyclical inflation and deflation, thereby improving device reliability while mitigating the harmful fibrotic response

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent implements periodic action through the cyclical inflation and deflation of the actuatable capsule. By repeatedly changing its volume over time, the capsule creates periodic mechanical stimuli that modulate strain, fluid flow, and cellular activity in the peri-implant tissue. This periodic action continuously challenges the fibrotic capsule formation process, leading to reduced fibrous capsule thickness and improved device longevity

Inventive Principle:

Principle #19Periodic action

2Object-affected harmful factors

If the device surface is modified to reduce fibrotic encapsulation, then foreign body response is mitigated, but device complexity increases

Engineering Contradiction:

Improveforeign body responseVSAvoiddevice structure

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the device into distinct functional components: the primary implantable medical device and a separate actuatable capsule. This capsule can be implanted separately or attached to the device surface, allowing the fibrotic encapsulation mitigation function to be isolated from the core device functionality. This modular approach reduces the complexity of modifying the entire device while still achieving the desired reduction in foreign body response

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The actuatable capsule serves as an intermediary element between the implantable medical device and the surrounding tissue. Rather than directly modifying the device surface chemistry or structure, the capsule acts as a mediator that creates favorable biomechanical conditions at the tissue interface. This intermediary approach simplifies the overall system by using a dedicated component to handle the foreign body response, leaving the core device functionality unchanged

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significant reduction in fibrous capsule thickness and myofibroblasts, enhanced pharmacokinetics, and increased drug delivery through the fibrotic capsule, demonstrating improved device functionality and reduced encapsulation.

Implementation Method 1

cyclical deflection of the soft tissue interfacing membrane

Methodology Applied

Scientific EffectCyclical deflection:

Implementation Method 2

altering the biomechanics of the soft tissue interface by altering strain, fluid flow and cellular activity

Methodology Applied

Scientific EffectBiomechanics modulation:

Implementation Method 3

adding a porous membrane (or a membrane that becomes transiently porous only upon actuation/deflection, or renders the native foreign body response porous)

Methodology Applied

Scientific EffectPorous membrane transport: Porosity

Implementation Method 4

increased transport of a drug analog and enhanced pharmacokinetics

Methodology Applied

Scientific EffectDrug diffusion: Diffusion

Data Source

PatentEP3989878B1An implantable medical device

Publication Date: 2026.01.28 UNIV OF GALWAY

Figure 1A
Figure 1B
Figure 1C

AI summary

An implantable medical device having a soft tissue interfacing surface comprises at least one soft actuatable capsule having a soft tissue interfacing deflectable membrane configured for cyclical deflection upon actuation of the capsule to modulate the biomechanics of the soft tissue interface during use. The actuatable capsule may comprise an actuation chamber containing a first fluid, a therapeutic chamber containing a second fluid, a deflectable membrane separating the actuation chamber and therapeutic chamber, and an actuation conduit in fluidic communication with the actuation chamber for pneumatic actuation of the actuation chamber. The therapeutic chamber comprises the soft tissue interfacing deflectable membrane which is configured to cyclically deflect during actuation of the capsule and modulate the biomechanics of the soft tissue interface by altering one or more of strain, fluid flow and cellular activity in peri-implant tissue at the soft tissue interface. Methods of reducing fibrotic encapsulation of an implantable medical device are also described.